Phaseline

Targets › CSF3R

CSF3R (Granulocyte colony-stimulating factor receptor): drug programs, companies and trials

15 programs from 15 companies in 39 trials: 21 Phase 2, 11 Phase 3, 4 Phase 1, 3 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.

Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differentiation and survival of cells along the neutrophilic lineage. (UniProt, Q99062)

Open in Phaseline: the race on CSF3R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital with Nanjing Medical UniversityPEG-rhG-GSF
Granulocyte colony-stimulating factor (pegylated)
CSF3RPhase 3Esophageal Squamous Cell CarcinomaNov 2026
SavaraRegramostim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 3Autoimmune Pulmonary Alveolar ProteinosisMay 2027
Kexing BiopharmPegfilgrastim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 3Neutropenia, Chemotherapy-Induced Febrile; Non-Hodgkin's Lymphoma; Multiple Myeloma; Esophageal Cancer …–
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityMecapegfilgrastim
Long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF)
CSF3RPhase 2Metastatic Breast CancerDec 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesTelpegfilgrastim Injection
PEGylated recombinant human granulocyte colony-stimulating factor (pegylated rhG-CSF)
CSF3RPhase 2Solid TumorsApr 2027
Qilu PharmaceuticalQLC2519
Modified G-CSF fused to human serum albumin (HSA) with reduced G-CSF receptor affinity
CSF3RPhase 2Pediatric Malignant Solid TumorJun 2027
Spectrum PharmaceuticalsEflapegrastim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 2Solid TumorsOct 2027
Affiliated Hospital of Nantong UniversityMecapegfilgrastim injection
Long-acting granulocyte colony-stimulating factor (G-CSF) analog; pegylated filgrastim
CSF3RPhase 2MyelosuppressionDec 2027
CSL BehringAnumigilimab (CSL324)
Granulocyte colony stimulating factor receptor antagonist
CSF3RPhase 2Sickle Cell DiseaseAug 2028
YaqritFilgrastim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 2Acute-On-Chronic Liver Failure; Early-stage Breast Cancer; Diminished Ovarian Reserve; Allogeneic Granulocyte Donation …Aug 2028
Institute of Hematology & Blood Diseases Hospital, ChinaMecapegfilgrastim
Long-acting G-CSF receptor agonist
CSF3RPhase 2Multiple Myeloma–
IRCCS San RaffaeleMyelostim (G-CSF)
Granulocyte-colony stimulating factor receptor agonist
CSF3RPhase 2Chronic Granulomatous Disease X-linked (X-CGD)–
Sun Yat-sen UniversityTelpegfilgrastim
Long-acting G-CSF receptor agonist
CSF3RPhase 2Chemotherapy-Induced Neutropenia–
National Cancer Center, KoreaTripegfilgrastim
G-CSF receptor agonist (pegylated G-CSF analog)
CSF3RPhase 2Unresectable Pancreatic Cancer–
Nanjing King-Friend Biochemical PharmaceuticalNKF-PEG
Pegfilgrastim biosimilar; granulocyte colony-stimulating factor (G-CSF) analog
CSF3RPhase 1Healthy ParticipantsNov 2026

Conditions

Solid Tumors (2) Autoimmune Pulmonary Alveolar Proteinosis (2) Multiple Myeloma (2) Non-Hodgkin's Lymphoma (2) Aplastic Anemia (2) Unresectable Pancreatic Cancer (1) Healthy Participants (1) Sickle Cell Disease (1) Myelosuppression (1) Esophageal Squamous Cell Carcinoma (1) Chronic Granulomatous Disease X-linked (X-CGD) (1) Pediatric Malignant Solid Tumor (1)

Modalities

protein or peptide (6), small molecule (4), mixed (4), antibody (1)

Companies

National Cancer Center, Korea (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Nanjing King-Friend Biochemical Pharmaceutical (1) CSL Behring (1) Savara (1) Affiliated Hospital of Nantong University (1) The First Affiliated Hospital with Nanjing Medical University (1) Institute of Hematology & Blood Diseases Hospital, China (1) Spectrum Pharmaceuticals (1) IRCCS San Raffaele (1) Qilu Pharmaceutical (1) Kexing Biopharm (1) Yaqrit (1) Sun Yat-sen University (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.